Rapid Therapeutic Science Laboratories, Inc. (RTSL) Cash & Current Investments (2016 - 2023)

Generated on {Timestamp} © BusinessQuant.com

Generated on {Timestamp} Powered by

Rapid Therapeutic Science Laboratories' Cash & Current Investments history spans 8 years, with the latest figure at $2160.0 for Q2 2023.

• For Q2 2023, Cash & Current Investments fell 98.07% year-over-year to $2160.0; the TTM value through Jun 2023 reached $2160.0, down 98.07%, while the annual FY2021 figure was $192484.0, 61.44% down from the prior year.
• Cash & Current Investments for Q2 2023 was $2160.0 at Rapid Therapeutic Science Laboratories, down from $17572.0 in the prior quarter.
• Across five years, Cash & Current Investments topped out at $919707.0 in Q3 2021 and bottomed at $1334.0 in Q1 2019.
• The 5-year median for Cash & Current Investments is $124189.5 (2019), against an average of $172987.6.
• The largest annual shift saw Cash & Current Investments surged 10111.09% in 2020 before it tumbled 98.07% in 2023.
• A 5-year view of Cash & Current Investments shows it stood at $136215.0 in 2019, then skyrocketed by 266.44% to $499146.0 in 2020, then tumbled by 61.44% to $192484.0 in 2021, then tumbled by 41.73% to $112164.0 in 2022, then crashed by 98.07% to $2160.0 in 2023.
• Per Business Quant, the three most recent readings for RTSL's Cash & Current Investments are $2160.0 (Q2 2023), $17572.0 (Q1 2023), and $112164.0 (Q2 2022).

Peer Comparison